What changed

The original sweep was framed as "AI for financial services." That's the buyer, not the domain.

• Scuttlebug is healthcare-data infrastructure sold to financial-services analysts — not a fintech product.
• Buyer = analysts at PE / CVC / hedge funds doing pharma asset due diligence.
• Domain = 21 public healthcare data sources (CMS, FDA, ClinicalTrials.gov, ChEMBL, MeSH, NHS, EMA…) cross-linked by a resolved taxonomy.
• Wedge = pre-joined data + AI interface, so analysts ask multi-source questions in minutes instead of 3–5 days of data engineering — and silent join failures don't destroy the answer.

Closest comparables in market: 9fin (UK alt-data + AI for credit analysts) · Causaly (UK biomedical AI search for pharma) · Pangaea Data (UK ML on clinical/scientific data, closest UK pre-seed precedent) · AlphaSense / Sentieo / Tegus · Komodo Health · BenchSci · Owkin.

Implication for the fund map

Most of the original Tier 1 was wrong vertical. The right list looks meaningfully different.

Scoring axes

A fund needs 2 of A/B/C plus D to be Tier 1 for Scuttlebug.

A fund with only A (alt-data, no healthcare) is still strong. Only B (healthcare-data, no investor-tooling) is moderate — they may not get the buyer. Only C is weak — applied AI is everywhere. Pure fintech-vertical = wrong vertical unless they have an explicit healthcare carve-out (Anthemis CommonAI is one).

Tier 1 — priority leads (1–10 of 20)

Highlighted = direct precedent (already wrote a cheque into a structurally identical thesis).

Tier 1 — priority leads (11–20 of 20)

Tier 1.5 — verify-and-pitch: Crane, Earlybird Fund VIII, GC Famiglia, Sequoia Arc Europe, Apex Ventures, Verve Ventures, Karista, IQ Capital, Hambro Perks, EBRD VC, Pentech (Series A scale).

Three warm-intro ladders

Set up before anything else. Highest leverage activity in the entire raise.

Bonus: a Behavox / Babylon / Skin Analytics operator opens Hoxton specifically.

Cap-table walk · Causaly ~$93M raised

Closest domain match. UK-based, biomedical AI search for pharma.

Caroline Xie (ICONIQ) and Carlos Gonzalez-Cadenas (Index) sit on the board.

Cap-table walk · 9fin ~$254M raised, $1.3B valuation

Closest format match. UK alt-data + AI for credit/debt analysts.

Fergal Mullen (Highland) on board · Alex Finkelstein (Spark) on board.

Cap-table walk · Pangaea Data

Closest UK pre-seed precedent. AI on biomedical / clinical data sold to pharma. All-UK cap table.

All five fund + angel names are immediate priority targets. They've already underwritten this exact thesis from London.

Mosaic mosaic.pe · NYC + Toronto · ~$18M+

AI deal-modeling for PE associates / VPs. Customers: Warburg Pincus, Bridgepoint, CVC, New Mountain, Evercore.

Disambiguation: mosaic.pe ≠ mosaic.tech (the FP&A platform). Different parent. The .pe is a deliberate "private equity" play.

Most actionable: Troy Pospisil — operator-investor archetype: vertical-AI-for-private-markets. Find via Ontra.ai network. Radical is too late for pre-seed; track for Series A.

Rogo NYC, London office · ~$310M+ · $2B valuation

Agentic AI for IB analysts, PE associates, asset-management analysts. >250 institutions / 35,000+ users.

Pre-seed-actionable: AlleyCorp · BoxGroup · Company Ventures · Mantis VC · Positive Sum · Jack Altman / Alt Capital. All US, but write into UK pre-seed.

Inven Helsinki · ~$14.4M raised

AI deal-sourcing for PE / M&A bankers / corp dev / consulting. Same persona as Scuttlebug.

Most actionable: Lifeline Ventures (Petteri Koponen) — Helsinki-based, leads pre-seed/seed (Wolt, Supercell, Smartly), now committed to "AI for private-markets dealmakers" exactly. Joint Effects also pre-seed-actionable. Ventech and Vendep are Series A.

Diligence Squared NYC + Europe customers · ~$5M raised

Closest comparable yet at the buyer level. AI voice agents conduct expert interviews at scale for PE / private credit / corporate due diligence.

Founders: Frederik Kofoed Hansen (CEO, ex-Blackstone SF/NY/London, ex-JPM) · Søren Biltoft (COO, ex-BCG PE) · Harshil Rastogi (Google AI engineer). Founded 2025; launched October 2025.

Most actionable: Y Combinator (W26/S26 — they backed a direct comp this cycle) · Amino Capital (Palo Alto AI/data thesis, near-direct comp investor) · the rest are small fast cheques useful as round fillers post-lead.

Strongest signal: the operator-founder archetype works. Hansen (ex-Blackstone London) is the prototype Scuttlebug should befriend / get an intro through.

Investors in 2+ comparable cap tables

Highest signal — these have already underwritten the thesis multiple times.

The first-30-emails list

UK / EU-actionable investors who have backed at least one direct comparable.

Pre-seed / Seed (UK or near-UK)

Seedcamp · Marathon VC · Entrepreneur First · Emerge Education · Matt Clifford (EF angel) · AI Seed · firstminute capital · IQ Capital (Cambridge) · Hambro Perks · Ascension Ventures · Frontline Ventures · 42cap (Munich) · Amino Collective (Berlin) · Fly Ventures · Visionaries Club · NJF Capital · Lifeline Ventures (Helsinki) · Joint Effects (Helsinki) · AlleyCorp (NYC) · BoxGroup (NYC) · Company Ventures (NYC) · Y Combinator (W26/S26) · Amino Capital (Palo Alto) · Relentless VC · Multimodal Ventures · TwentyTwo VC

Series A (UK / EU) — for next-round mapping

Pentech Ventures (Edinburgh) · EBRD VC · Highland Europe · Cathay Innovation · Otium Capital · Index Ventures · Eight Roads / F-Prime · Generation IM · Greycroft (London office) · Ventech

Strategic angels (UK-reachable)

Pharma: Dr Jonathan Milner (Abcam) · Sir Peter Job (Reuters) · Tom Glocer (Reuters) · Olivier Pomel (Datadog) · Alex Gorsky (J&J) · Jean-Paul Clozel (Actelion).
PE / private markets: Troy Pospisil (Ontra) · Henry Kravis (KKR) · Patrick O'Shaughnessy (Positive Sum) · Jack Altman (Alt Capital) · John Megrue (ex-Apax).
Tech / fintech-AI: Charlie Songhurst · Brent Hoberman (firstminute) · Matt Clifford (EF) · Risto Siilasmaa (F-Secure) · Saul / Robin Klein · Hinrikus / Tamkivi (Plural) · John Taysom · Eileen Burbidge.

UK healthtech specialists

Funds the original fintech-framed sweep missed.

Continental Europe healthtech specialists

Strategic angels — three archetypes

Build this pool deliberately. Two or three of these in the round compound the VC-side narrative.

Skip · wrong vertical for Scuttlebug

Originally Tier 1 for fintech-AI. Wrong fit for healthcare-data product.

Skip · other reasons

Wrong-corporate accelerators

Founders Factory Aviva (insurance) · Techstars NatWest (fintech) · ABN-Techstars Future of Finance (banking). Apply only if a healthtech / pharma-analytics corporate cohort exists — verify with each programme's team.

Outreach plan · Phases 1 & 2

Phase 1 — warm-intro ladders (highest ROI)

1. Pangaea Data operator → IQ Capital, Hambro Perks, Ascension Ventures + Milner, Job, Taysom angels.
2. Causaly operator → Marathon, EF/Clifford, Emerge, Pentech, EBRD, Index, ICONIQ, Visionaries Club. Pattern-matches into Hoxton, MMC, Octopus, Plural.
3. 9fin operator → Seedcamp, Spark, Highland, Fly, Redalpine, AI Seed, 500 Global. Pattern-matches into Crane, Plural, Air Street.

Phase 2 — Tier 1 funds (20 names)

Cold-friendly partners with public engagement: Hussein Kanji (Hoxton X @hkanji) · Simon Menashy (MMC, LinkedIn) · Joe Stringer/Will Gibbs (Octopus) · Vinoth Jayakumar (Ascension, EIS angle) · Daria Saharova (Speedinvest Health) · Carina Namih/Taavet Hinrikus (Plural) · Gabriel Matuschka (Fly, reference 9fin) · Robert Lacher/Judith Dada (Visionaries, reference Causaly) · Marta Gaia Zanchi (Nina Capital, LinkedIn) · Brent Hoberman/Spencer Crawley (firstminute, reference Owkin) · Carlos Gonzalez-Cadenas (Index, Causaly board) · Nathan Benaich (Air Street, RAAIS) · Reece Chowdhry (Concept) · Eckhardt Weber (Heal Capital) · Mads Jensen (Lunar, technical one-pager) · Will Prendergast (Frontline) · Mark Evans (Kindred) · Patrick Newton (Form, regulatory wedge) · Panos Papadopoulos (Marathon, reference Causaly) · Sia Houchangnia (Seedcamp, reference 9fin) · Christoph Ruedig (AlbionVC, reference HealthTech Market Map).

Outreach plan · Phases 3 & 4

Phase 3 — accelerators & public money (parallel)

• Y Combinator W26 / S26 — Scuttlebug is a strong YC fit. Diana Hu / Aaron Epstein read healthcare-AI.
• Sequoia Arc Europe — Spring + Fall windows, $1M upfront, sector-agnostic AI cohort.
• Innovate UK · Innovation Loans — £100k–£2M at 7.4% pa for UK startups; healthcare-data is in scope.
• EIC Pre-Accelerator — €75k pre-seed grant.
• Verify if Founders Factory or Techstars run a healthtech / pharma-analytics corporate cohort. Skip Aviva / NatWest / ABN-Techstars Future of Finance.

Phase 4 — round fill via deliberate angel pool

• Pharma operators: Milner, Job, Pomel, Gorsky framing.
• PE operators: Pospisil (Ontra), O'Shaughnessy (Positive Sum), Altman (Alt Capital) framing.
• Fintech-AI operators: Songhurst, Hoberman, Clifford, Saul/Robin Klein, Plural personals.
• Nordic angle: Siilasmaa, Petteri Koponen personal cheque if Inven precedent applies.
• Syndicates: Odin SPVs, Cultivate (Blossom), Atomico Angel Programme, Common Magic.

Suggested timing

1. Week 1–2: Build the three warm-intro ladders. LinkedIn 2nd-degree mining for Pangaea Data, Causaly, 9fin operators.
2. Week 1–4: Open YC, Sequoia Arc, Innovate UK Innovation Loans, EIC Pre-Accelerator applications in parallel. These compound rather than substitute.
3. Week 2–6: Cold-friendly partner outreach (21 named partners listed). Aim 4 calls/week.
4. Week 4–8: Warm-intro pipeline kicks in to Tier 1 funds.
5. Week 6+: Once a credible lead is converging, open Phase 4 angels & syndicates to fill the round.

CRM each contact by: fund/person · partner of record · stage of conversation · last contact · owed-action · source-of-intro · feedback. The source-of-intro field is what tells you which warm-intro ladder is compounding fastest.

Sources & method

• Re-evaluation of the 135-fund original sweep (funds_preseed_eu.md) against Scuttlebug's actual thesis after reading the CVC presentation.
• Three additional research agents:
  • UK + EU healthtech specialist VCs (gap from original fintech-framed sweep)
  • Cap-table research on Causaly, 9fin, AlphaSense, Sentieo, Tegus, Komodo, Definitive, BenchSci, Owkin, Pangaea Data, Nostos Genomics, Innoplexus, plus alt-data tooling
  • Mosaic / Rogo / Inven full timelines (user-flagged comparables)
• Primary sources: each fund's own site + 2024–2026 press (TechCrunch, Sifted, EU-Startups, Tech.eu, FinSMEs, ArcticStartup, Crunchbase, Tracxn, PitchBook).
• Long-form: funds_evaluation_scuttlebug.md in this repo — every entry has source links, partner names, recent portfolio examples, and verdicts.

Decay caveat: investor data ages fast — fund partners move, theses shift, funds wind down. Re-verify any single data point before acting on it.

Scoring methodology

Each fund scored out of 10 across four axes. Tie-break: signal-to-effort.

Top 10 · scores 9–10

Pitch first. Direct precedent + clean seed cheque size + UK partner.

Tier 1.5 · scores 8 · also strong

Tier 2 · scores 7 · pitch with strong framing

Tier 2.5 + Tier 3 · scores 4–6

Lower priority; pitch with warm intro or strong framing.

Tier 4 · scores 0–3 · skip / wrong fit

First-30-emails list

Rank-ordered by signal-to-effort. Run them in waves of 6–8 over 4 weeks.

Plus parallel: Y Combinator W26/S26 (backed Diligence Squared this cycle) · Lifeline Ventures Helsinki (led Inven seed) · Sequoia Arc Europe · Innovate UK Innovation Loans.